Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse‐Transcriptase Inhibitors in HIV Type 1–Infected Children
Clinical Infectious Diseases2008Vol. 46(10), pp. 1601–1608
Citations Over TimeTop 20% of 2008 papers
Tim R. Cressey, Hannah Green, Saye Khoo, Jean‐Marc Tréluyer, Alexandra Compagnucci, Yacine Saïdi, Marc Lallemant, Diana M. Gibb, David M. Burger, Paediatric European Network for Treatment of AIDS II Study Group
Abstract
In children with virological suppression who experienced interruption of treatment with an NNRTI, staggered or replacement stopping strategies for a median of 9 days for nevirapine and 14 days for efavirenz were not associated with the selection of NNRTI resistance mutations.
Related Papers
- → Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors(1999)70 cited
- → Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana(2013)15 cited
- → Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse‐Transcriptase Inhibitors in HIV Type 1–Infected Children(2008)20 cited
- → Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy(2014)10 cited
- → Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children(2016)9 cited